Brokerages expect that Medidata Solutions, Inc. (NASDAQ:MDSO) will post $141.03 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Medidata Solutions’ earnings, with the lowest sales estimate coming in at $140.40 million and the highest estimate coming in at $142.34 million. Medidata Solutions posted sales of $120.06 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 17.5%. The firm is expected to issue its next earnings results on Tuesday, October 24th.

On average, analysts expect that Medidata Solutions will report full-year sales of $141.03 million for the current year, with estimates ranging from $550.10 million to $558.00 million. For the next fiscal year, analysts anticipate that the company will post sales of $652.31 million per share, with estimates ranging from $642.33 million to $669.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Medidata Solutions.

Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Tuesday, July 18th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.28 by $0.03. Medidata Solutions had a return on equity of 11.14% and a net margin of 7.07%. The firm had revenue of $137.41 million for the quarter, compared to analysts’ expectations of $134.28 million. During the same period last year, the firm earned $0.24 EPS. The firm’s revenue was up 19.9% compared to the same quarter last year.

A number of research analysts have recently issued reports on MDSO shares. Bank of America Corporation started coverage on shares of Medidata Solutions in a research note on Tuesday, June 6th. They issued a “buy” rating and a $85.00 target price for the company. BidaskClub cut shares of Medidata Solutions from a “buy” rating to a “hold” rating in a research note on Wednesday, June 14th. Morgan Stanley set a $74.00 target price on shares of Medidata Solutions and gave the company a “buy” rating in a research note on Wednesday, June 14th. SunTrust Banks, Inc. lifted their target price on shares of Medidata Solutions from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, June 27th. Finally, Piper Jaffray Companies lifted their target price on shares of Medidata Solutions to $87.00 and gave the company an “overweight” rating in a research note on Friday, July 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $82.91.

In related news, COO Michael L. Capone sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $74.53, for a total value of $372,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.80% of the company’s stock.

A number of hedge funds have recently bought and sold shares of MDSO. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Medidata Solutions by 10.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock worth $171,000 after purchasing an additional 208 shares during the last quarter. LS Investment Advisors LLC raised its position in Medidata Solutions by 44.6% in the 1st quarter. LS Investment Advisors LLC now owns 3,310 shares of the company’s stock worth $191,000 after purchasing an additional 1,021 shares during the last quarter. World Asset Management Inc bought a new position in Medidata Solutions in the 1st quarter worth approximately $201,000. Miles Capital Inc. bought a new position in Medidata Solutions in the 1st quarter worth approximately $202,000. Finally, Oppenheimer & Close LLC bought a new position in Medidata Solutions in the 1st quarter worth approximately $210,000. Hedge funds and other institutional investors own 97.53% of the company’s stock.

Shares of Medidata Solutions (NASDAQ MDSO) opened at 75.86 on Friday. The company has a 50-day moving average price of $74.69 and a 200 day moving average price of $69.86. Medidata Solutions has a 52-week low of $46.10 and a 52-week high of $85.92. The firm has a market capitalization of $4.30 billion, a PE ratio of 122.55 and a beta of 1.81.

WARNING: “$141.03 Million in Sales Expected for Medidata Solutions, Inc. (MDSO) This Quarter” was first published by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/17/141-03-million-in-sales-expected-for-medidata-solutions-inc-mdso-this-quarter.html.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.